The White House denied reports it had tried to block the new FDA guidance.
October 7, 2020, 1:36 AM
• 7 min read
The Food and Drug Administration has told companies working on COVID-19 vaccines that it expects at least two months of follow-up on clinical trial participants after they complete a full regimen of a vaccine, meaning one likely couldn’t be authorized before Election Day for large-scale use or even emergency use in a limited way, despite the president’s promises.
The Washington Post and The New York Times have reported the White House has blocked the FDA from posting the tougher standards for vaccines as President Donald Trump has repeatedly promised a vaccine on or near Election Day on Nov. 3 and suggested it would be widely available much sooner, contradicting experts close to the process who say it will